Stockwinners Market Radar for November 08, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:17 EST Cathie Wood's ARK Investment bought 421K shares of Coinbase today

18:47 EST Affirm CEO: We grew on every metric we care about - In an interview on CNBC's Mad Money, Max Levchin said, "We're doing pretty great, we took market share. We have controls to hit the numbers we feel we must hit." He noted that there is eventually an impact that rising rates have on the company's margins, but it has tools to mitigate those impacts. Levchin expects Affirm to grow and turn profitable "on schedule."

18:24 EST Zoom Video CFO: We continue to innovate - In an interview on CNBC's Mad Money, Kelly Steckelberg said the company is seeing continued growth with Zoom IQ and requests to extend it. "The future of work has changed and we're the company that has helped define that," she added. Zoom will continue to be "the platform of choice - customers love us." She noted that 10% of Zoom's customers account for approximately 50% of its ARR.

17:47 EST Affirm says slowing economy, worsening consumer credit to hamper GMV growth - The company states: "With credit quality as our most important guardrail, we plan to continue to grow GMV while maintaining strong unit economics and managing our operating expenses thoughtfully. This quarter we delivered $182 million of Revenue Less Transaction Costs against costs of approximately $200 million. Getting very close! With macroeconomic volatility projected to continue, we don't expect this process to be easy. It's likely that the slowing economy and worsening consumer credit will hamper GMV growth in the near-term. The Fed's accelerated rate changes are causing significant dislocations in debt capital markets, and we expect that to put temporary pressure on RLTC as a percentage of GMV."

17:37 EST SLB CAO Guild sells 20,053 common shares - In a regulatory filing, Schlumberger CAO Howard Guild disclosed the sale of 20,053 common shares of the company on November 7 at a price of $53 per share.

17:28 EST Adeia, Frndly TV enter long-term license renewal - Adeia announced that Frndly TV has entered into a long-term renewal to license Adeia's Media patent portfolio. As one of the fastest growing Pay-TV streaming services in the U.S., Frndly TV offers consumer friendly, live TV programming over-the-top, or OTT, and has become one of the top 10 largest virtual Multichannel Video Programming Distributors, or vMVPDs.

17:21 EST Starboard reports 11.5% stake in Acacia Research - Starboard purchased the securities based on the belief that they were "undervalued and represented an attractive investment opportunity." The filing allows for activism. On October 30, Starboard Value LP and certain of its affiliates entered into a Recapitalization Agreement with Acacia Research, pursuant to which, among other things, Starboard and the company agreed to enter into a series of transactions to restructure Starboard's existing investments in it.

17:09 EST Disney sees FY23 revenue growth at high-single-digit rate - CFO McCarthy says: "Assuming we do not see a meaningful shift in the macroeconomic climate, we currently expect total company's FY23 revenue and segment operating income to both grow at a high single-digit percentage rate versus FY22."

17:06 EST Disney CFO sees FY23 capex increasing to $6.7B

17:05 EST Disney says DTC operating results to improve by at least $200M in Q1 - CFO McCarthy states: "With our expectation that peak losses are now behind us, DTC operating results should improve going forward as we lay the foundation for a sustainably profitable business model. In the first quarter of fiscal 2023, we expect direct-to-consumer operating results to improve by at least $200 million versus the fourth quarter of fiscal 2022, with larger improvement expected in Q2, reflecting a couple of key factors. First, our recently announced price increases across our Direct-to-Consumer offerings in the U.S. should begin to modestly benefit ARPU and subscription revenue in the first quarter. However, given that the Disney+ price increase will not go into effect until towards the end of Q1, this benefit will be realized more fully in the second quarter. Similarly, we do not expect the launch of the advertising-supported tier of Disney+ in December to provide a more meaningful financial impact until later this fiscal year."

17:02 EST Disney CFO says advertising landscape remains fluid - Say: "ESPN advertising revenue in Q4 was down 23% year-over-year. However, adjusting for the timing impact of the NBA Finals, it was down roughly 2%. Note that in Q1 of fiscal 2023, we also expect to see a timing impact versus the prior year from 2 college football playoff games that are shifting into the second fiscal quarter this year versus the first quarter last year. Quarter-to-date, ESPN domestic cash advertising sales are pacing down, reflecting in part the absence of these 2 CFP games. The advertising landscape remains fluid. The sports marketplace, in particular, is delivering strong audiences across our platforms with marketers looking to take advantage of live events and several categories, including political, pharma, insurance and restaurants, have continued to show relatively stable demand while others remain cautious in anticipation of potential economic softness." Comments taken from Q4 earnings conference call.

17:00 EST Disney CFO expecting strong holiday season in Q1 - CFO Christine McCarthy says: "We are also making meaningful progress on the return of international visitors to our domestic parks, particularly at Walt Disney World, where the mix of international attendance in the fourth quarter was roughly in line with pre-pandemic levels. Looking towards fiscal 2023, while we continue to monitor our booking trends for any macroeconomic impacts, we are still seeing robust demand at our domestic parks and are anticipating a strong holiday season in Q1."

16:58 EST Lucid Group falls 10% to $12.03 after Q3 results

16:58 EST Lucid Group plans to open reservations for Project Gravity SUV in early 2023 - "I'm delighted to say that we've made significant progress toward achieving our 2022 production target of 6,000-7,000 vehicles. We had record quarterly production of 2,282 vehicles, more than triple Q2, and deliveries of 1,398, which was more than double Q2," said Peter Rawlinson, Lucid's CEO and CTO. "I'm also pleased to announce that we've now proven our ability to produce 300 cars a week, with a visible pathway to our next incremental ramp up." "We continue to have strong demand with over 34,000 reservations as of November 7, 2022," said Sherry House, Lucid's CFO. "We plan to open reservations for Project Gravity SUV in early 2023, which we believe will unlock a very large and incremental addressable market for us. We remain intently focused on scaling the business and continue to expect to see significant growth in revenue as delivery volumes ramp."

16:55 EST Zendesk to slash 4.9% of workforce, or roughly 300 employees - According to a regulatory filing, on November 3, 2022, the board of directors of Zendesk approved a plan to reduce Zendesk's current workforce by approximately 300 employees, representing approximately 4.9% of Zendesk's total global workforce. This decision was based on cost-reduction initiatives intended to reduce operating expenses and sharpen Zendesk's focus on key growth priorities. Zendesk currently estimates that it will incur charges of approximately $28M in connection with the reduction in force, primarily consisting of severance payments, employee benefits and related costs. Zendesk expects that approximately $8M of these charges will be incurred in the fourth quarter of 2022, and that the reduction in force will be substantially complete by first quarter of 2023, subject to local law and consultation requirements, which may extend the process beyond the first quarter of 2023 in certain countries. Of the total charge, approximately $20M are expected to be future cash expenditures. The charges Zendesk expects to incur are subject to assumptions, including local law requirements, and actual expenses may differ materially from the estimates disclosed above.

16:54 EST Affirm falls 17% to $12.89 after Q2, FY23 revenue guidance misses estimates

16:45 EST XP Inc. increases buyback program by R$1B - XP Inc. announced a R$1B increase in the program opened in last May. "As partners whose personal holdings are concentrated in XP Inc. shares and that are confident with its success, we are 100% aligned with all our shareholders," the company said. "We look forward to dividends, new share buybacks and greater returns for our business, preserving our management and risk principles which are vital to long-term, sustainable success."

16:42 EST Regeneron: FDA approves Libtayo in combination with platinum-based chemotherapy - Regeneron Pharmaceuticals announced that the U.S. FDA has approved the PD-1 inhibitor Libtayo in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer with no EGFR, ALK or ROS1 aberrations. Patients must either have metastatic or locally advanced tumors that are not candidates for surgical resection or definitive chemoradiation. Patients may be treated with this combination irrespective of PD-L1 expression or histology.

16:42 EST Ampio to implement fifteen-to-one reverse stock split - Ampio Pharmaceuticals announced that effective November 9, the Company will amend its certificate of incorporation to implement a fifteen-to-one reverse stock split. As a result of the reverse stock split, every fifteen shares of common stock issued and outstanding automatically will be combined into one share of common stock, with no change in the 0.01c par value per share. No fractional shares will be outstanding following the reverse stock split. Holders of fractional shares will be entitled to receive the number of shares rounded up to the next whole number. Immediately prior to the reverse stock split, the Company had 226,286,867 shares of common stock outstanding, which will be proportionately reduced to reflect the fifteen-to-one reverse stock split. The reverse stock split will not change the number of authorized shares under the Company's certificate of incorporation, which will continue to consist of 310,000,000 shares authorized, of which 10,000,000 shares are designated as preferred stock and 300,000,000 shares are designated as common stock. The Company is implementing the reverse stock split in order to attempt to increase the per share price of its common stock as part of its strategy to seek the termination of the trading suspension on the NYSE American, so that trading may resume on that market. The CUSIP identifier for the Company's common stock following the reverse stock split is 03209T 208. The Company's common stock will begin trading on a post-split basis, on the OTC Pink Open Market, when the market opens on November 10.

16:39 EST Mirati Therapeutics names Alan Sandler, M.D. as chief medical officer - Mirati Therapeutics announced the appointment of Alan Sandler, M.D., to the position of executive vice president and chief medical officer. In his role, Dr. Sandler will provide leadership and direction over clinical development and operations, regulatory affairs, drug safety and asset development strategy and report to David Meek, CEO. As part of the transition, Dr. James Christensen, executive vice president and chief scientific officer, will also report to Meek. Most recently, Dr. Sandler was president and global head of oncology for Zai Lab where he led global oncology development for the company.

16:35 EST Upstart Holdings trading resumes

16:29 EST New Mountain Finance says John Kline to become CEO effective January 1, 2023 - Effective January 1, 2023, John R. Kline will become Chief Executive Officer of the Company, in addition to continuing in his role as President and Director. Mr. Kline joined New Mountain in 2008 and has been a senior executive within New Mountain Capital's credit effort since its inception that year. Robert A. Hamwee will be moving into the role of Vice Chairman of the board of directors where he will continue to serve the Company as a Director. Further, he will remain a member of the Company's investment committee and as a Managing Director of New Mountain Capital.

16:27 EST IAC CEO says 'will fix mistakes' at both IAC and Angi - IAC CEO Joey Levin said in the company's quarterly letter: "This letter is my first as CEO of both IAC and Angi, two companies in similar situations. Perceptions of both IAC and Angi have swung from extreme confidence to extreme skepticism. We could all challenge the rationality of the extremes, but the general shift in sentiment has been warranted. I usually don't believe anyone's as good or bad as their most recent results may indicate, but we've had some big wins and more recently, some misses, and that reality will color current perceptions. Fortunately, I do believe our mistakes to be mostly temporary, and with a little time, we will fix them... Of course, we have opportunities throughout IAC to increase value, which are covered below, but I'm focused heavily on Angi right now given the scale of the opportunity and the potential improvement in both near-term and long-term profit relative to today." Reference Link

16:26 EST Argan's Gemma Power receives notice to proceed for power project in Ohio - Argan announced that on November 3, 2022 its wholly owned subsidiary, Gemma Power Systems, received full notice to proceed on an engineering, procurement and construction services contract with Clean Energy Future-Trumbull, LLC, an affiliate of Clean Energy Future, LLC of Manchester, Massachusetts, the developer of the Trumbull Energy Center, a 950 MW natural gas-fired power plant in Lordstown, Ohio. Gemma has commenced project activities. "We are excited to build the next state-of-the art facility for CEF-Trumbull (an international consortium of KOSPO, KIND and Siemens Energy), a new customer for us," said Charles E. Collins, IV, Chief Executive Officer of Gemma. "Our team is looking forward to delivering a great project experience to the CEF-Trumbull team, and continuing to develop lasting ties with the local community." This 950 MW natural gas-fired combined cycle power station will consist of two Siemens Energy SGT6-8000H gas fired, high efficiency, combustion turbines with two heat recovery steam generators and a single steam turbine. "We anticipate successfully working again with Siemens Energy, a leader in combustion turbine technology, on this important project to deliver long-term, reliable power supply in the Ohio area," said Collins.

16:24 EST American Equity announces strategic partnership with 26North - American Equity Investment Life Holding Company announced that it is entering into a long-term partnership with 26North Partners LP, a multi-asset platform founded and led by Josh Harris, in which American Equity has made a strategic investment. Anant Bhalla, Chief Executive Officer and President of American Equity, will join the Board of Directors of 26North. A Bermuda-based reinsurer, AeBe ISA Ltd., which is affiliated with 26North, has reinsured approximately $4.3B of GAAP reserves of American Equity fixed indexed annuity policies from 2008 and 2010. American Equity estimates that this will generate an initial capital release in excess of $250M and generate a positive ceding commission, thereby growing AEL's revenue-generating reinsured liabilities. Anant Bhalla, Chief Executive Officer and President of American Equity, said, "This partnership with 26North is a further step in our AEL 2.0 strategy to deliver significant value to all shareholders. The strategy is aligned with policyholders through our unique go-to-market and investment management approaches and capital-light structure. We continue to refine a capital-efficient business model to deliver superior, sustained returns for our shareholders and further strengthen our robust balance sheet. This deal will enable greater capital flexibility for AEL as we benefit from 26North's investment expertise to deliver on attractive opportunities across private asset classes. We are proud to add 26North to our outstanding investment partner ecosystem and further advance our transformation into a hybrid, diversified financial services firm."

16:21 EST Danimer Scientific narrows FY22 adjusted EBITDA view to ($45M) to ($40M) - Prior guidance was ($45M)-($35M). The company states: "Danimer remains focused on making disciplined investments in its operational platform and infrastructure that will allow it to capture significant opportunities for its products in coming years. Based on results through September 2022 and increased visibility through year end, the Company is narrowing its Adjusted EBITDA outlook for the full year 2022, which it now expects to be in the range of $(45) million to $(40) million, compared to $(22.6) million in 2021. The Company now expects full year capital expenditures to be in the range of $165 million to $170 million, inclusive of capitalized interest and internal labor and overhead, with a year-end cash balance to be in the range of $60 million to $65 million. Looking beyond 2022, the Company expects its PHA-based revenues to drive a significant increase in the Company's overall profitability. The Company remains confident in its ability to execute against its objectives with a prudent focus on profitability and cash management."

16:18 EST Revance sees operating expenses at upper end of prior forecast - The company sates: "Revance expects its 2022 GAAP and non-GAAP operating expenses to be on the upper end of its previously announced guidance ranges of $375 million to $400 million and $260 million to $280 million, respectively. With current cash, cash equivalents and short-term investments of $378.6 million, an additional $100 million of notes available for issuance through Athyrium Capital, and anticipated revenues and expenditures, management projects that the company's U.S. aesthetics portfolio (DAXXIFY(TM), RHA(R) Collection, OPUL(R)) will be funded to cash flow breakeven."

16:18 EST News Corp. says Special Committee has not decided on pursuit of Fox deal - In October 2022, News Corp. (NWSA) announced that its Board of Directors, following the receipt of letters from K. Rupert Murdoch and the Murdoch Family Trust, has formed a special committee of independent and disinterested members of the Board to begin exploring a potential combination with Fox (FOX). The letters indicated that Mr. Murdoch and the Murdoch Family Trust will not vote in favor of a transaction unless it is both recommended by the Special Committee and approved by a majority vote of the shares held by non-affiliated stockholders entitled to vote. The Special Committee, in consultation with its independent financial and legal advisors, will evaluate the Potential Transaction. The Special Committee has not made any determination with respect to the Potential Transaction, and there can be no certainty that the Company will engage in the Potential Transaction. Neither the Company nor the Special Committee intends to disclose further developments regarding the Special Committee's work until it deems such disclosure is appropriate or required.

16:14 EST American Vanguard sees FY adjusted EBITDA $80M

16:11 EST Grocery Outlet announces CEO transition plan, Sheedy to become CEO - Grocery Outlet Holding announced that effective January 1, 2023, Eric Lindberg will transition from the role of Chief Executive Officer to Chairman of the Board, and RJ Sheedy, currently the Company's President, will become President and Chief Executive Officer, CEO. Sheedy also will be appointed to the Board, and Erik Ragatz, currently Chairman of the Board, will assume the role of Lead Independent Director. Sheedy brings more than 20 years of experience in the grocery and retail industries. He joined Grocery Outlet in 2012 and has served as the Company's President since 2019.

16:10 EST Aflac raises dividend 5%, announces 100M share repurchase program - Aflac announced that its Board of Directors has declared the first quarter dividend of 42c per share, payable on March 1, 2023, to shareholders of record at the close of business on February 15, 2023. This represents a 5.0% increase over the previously declared fourth quarter dividend. Additionally, its Board of Directors authorized the purchase of up to 100M shares of its common stock. This authorization is in addition to the 25.6M shares as of September 30, 2022, that remained under the August 11, 2020 authorization, bringing the total number of shares available for purchase to approximately 125.6M. The company anticipates that the repurchase of shares will be conducted from time to time in open market or negotiated transactions, depending on market conditions.

16:09 EST Alarm.com sees Q4 SaaS and license revenue $130.5M-$130.7M

16:08 EST Veritone says Ryan Steelberg will become CEO on January 1 - Veritone announced new roles for co-founders Chad Steelberg and Ryan Steelberg, effective January 1, 2023. Chad Steelberg, who has served as Chief Executive Officer and Chairman of the Board since Veritone's inception in June 2014, has indicated he will resign as Chief Executive Officer on January 1, 2023 but will remain Chairman of the Board. Ryan Steelberg, who has served as President and a member of the Board, will become Veritone's Chief Executive Officer on January 1, 2023, where he will continue to drive innovation and elevate the company's product offerings. Ryan Steelberg will also continue to serve as a member of the Board.

16:07 EST Array Technologies appoints Jokinen to board of directors - Array Technologies announced the appointment of Tracy Jokinen to the Company's Board of Directors, replacing Ron Corio, effective on November 8, 2022. Jokinen has over 25 years' experience in finance and accounting roles across various industries. Most recently, she served as Chief Financial Officer of Vyaire Medical.

16:04 EST Axon confident in LT financial goal of profitably delivering 20%+ topline CAGR

16:01 EST Upstart Holdings trading halted, news pending

15:16 EST Gold Fields terminates arrangement agreement with Yamana Gold - "As a result of Yamana Gold entering into an arrangement agreement with Pan American Silver and Agnico Eagle Mines and announcing a change in recommendation, Gold Fields has terminated the arrangement agreement in respect of the transaction. In accordance with the terms of the arrangement agreement, Yamana is required to pay Gold Fields a termination fee in the amount of US$300M within two business days from the date hereof," Gold Fields announced.

14:35 EST FedEx CFO projecting 'lower demand outlook for the foreseeable future' - FedEx CFO Michael Lenz said while speaking at the Robert W Baird Global Industrial Conference: "Look, we absolutely will realize more of the structural cost savings in the second half of the year. That's where you get more of the benefits start to roll in principally from -- at Express, the flight reductions. When you park the aircraft, particularly the older airplanes that we're parking, you're deferring a maintenance event, which is a significant expense. While at the same time, you have relatively low ownership costs on those. So it's an operationally and financially flexible way to manage capacity there. So as I said, we're projecting a lower demand outlook for the foreseeable future here. I don't have a perfect crystal ball to say what the overall macro environment will be. Don't have a full year earnings outlook for FY '23. So I don't have any specific projection to give you there, but rest assured, as some of these specifics that I was highlighting illustrate, we are fully committed to continuing to take the actions we need for changed expectations of what the operating environment is."

14:13 EST Zoom debuts Zoom Mail and Calendar for 'more communication and collaboration' - Joseph Chong, Head of Product, Solutions, and Industry Marketing for Zoom (ZM) Video blogged, in part: "We're taking another step forward to help users seamlessly access the tools they need directly in the easy-to-use Zoom app. With Zoom Mail and Calendar Clients (beta), users will get even more communication and collaboration capabilities in Zoom One and reduce the "toggle tax." Users will be able to work more efficiently, quickly access their communications, and easily schedule and join meetings-all from Zoom! The Zoom Mail and Calendar Services (beta) are targeted at small-to medium-business customers who particularly value email privacy. The Zoom Mail Service will provide end-to-end-encrypted email when messages are sent directly between active Zoom Mail Service users, and the Zoom Calendar Service will include an appointment booking feature, an easy way for participants to select an available time to meet on Zoom. For more information on Zoom Mail and Calendar, read our announcement blog...We understand the need for connection and simplified communication in a hybrid work world, and one thing we have learned is that people miss spontaneous conversations and collaboration when they worked side-by-side. To help make those connections easier and bridge the gap between workers in different locations, we're introducing a human-centered approach to virtual interaction - Zoom Spots...Coming in early 2023, Zoom Spots is Zoom's virtual coworking space...." The Fly notes that Microsoft (MSFT) and Google (GOOG,GOOGL) have email and calender features. Reference Link

13:59 EST Terex exec Hegarty sells 20,000 common shares - In a regulatory filing, Terex president of Materials Processing Kieran Hegarty disclosed the sale of 20,000 common shares of the company on November 7 at a price of $42.49 per share.

13:55 EST Lilly Endowment sells over $23M in Eli Lilly shares - Beneficial Owner of Eli Lilly & Co, Lilly Endowment, disclosed in a regulatory filing that it had sold 63,585 shares of Eli Lilly at $363.94 per share on November 7, for a total transaction amount of $23,141,049.

13:45 EST Coinbase investigating network connectivity issues - Coinbase said in a system status message posted to its site: "We're currently experiencing network connection issues for Coinbase.com web and mobile. This could result in difficulty signing in and slow loading across web and mobile. We're currently investigating the issue to fix." Reference Link

13:13 EST Air Products to receive C$475M in funding for Alberta hydrogen complex - The Canadian federal and provincial governments announced approximately C$475M in project funding for Air Products' multi-billion-dollar net-zero hydrogen energy complex in Alberta. "The facility, already being executed, will make Edmonton, Alberta the centre of western Canada's hydrogen economy and set the stage for Air Products to operate one of the most competitive and lowest-carbon-intensity hydrogen networks in the world," the company stated. Under separate agreements, Air Products will receive C$300M from the Strategic Innovation Fund, the Government of Canada's program designed to spur innovation for a better Canada by providing funding for large projects and national innovation ecosystems; over C$160M from the Alberta Petrochemicals Incentive Program, part of Alberta's Recovery Plan to bring multi-billion dollar investments to industrial projects throughout Alberta; and C$15M, which was previously announced, from Emissions Reduction Alberta's Shovel-Ready Challenge.

13:02 EST U.S. Steel announces tentative agreement with United Steelworkers - United States Steel announced that it has reached a tentative agreement with the United Steelworkers, or USW, on a new four-year contract covering approximately 11,000 USW-represented employees at the company's domestic flat-rolled facilities, iron ore mining facilities and applicable tubular operations. The tentative agreement remains subject to ratification. "We are pleased to have reached a tentative agreement with the USW that supports our unionized workforce while balancing the interests of all our stakeholders towards our Best for All future. I appreciate the efforts of both sides to work towards a responsible and mutually beneficial agreement. The time spent resulted in a contract that truly is Best for All. We leveraged our strong balance sheet to reward union employees with a bonus and strong base wages. We also leveraged our overfunded pension and OPEB plans to support the benefits provided to our employees. The tentative agreement reflects our core belief that when U. S. Steel does well, employees do well. Strong base wage increases and benefit enhancements to support our employees' wellbeing are key parts of this tentative agreement because we know their hard work is essential to delivering sustainable steel solutions for people and planet and enhancing our customer satisfaction," said David Burritt, President and CEO of U. S. Steel.

12:29 EST Auburn National president, CEO Bob Dumas to retire, David Hedges to succeed - Auburn National Bancorporation announced that Robert Dumas has decided to retire as President and CEO of the Company and its subsidiary, AuburnBank on December 31, 2022 after a distinguished 39-year career with the Company and the Bank. Mr. Dumas will continue to serve as Chairman of the board of directors and a director of the Company and the Bank. The Board of Directors of the Company and the Bank have elected David Hedges, the current Executive Vice President and CFO, to serve as a director of the Company and the Bank and to succeed Mr. Dumas as President and CEO of the Company and the Bank effective January 1, 2023. As part of this transition, James Walker, currently the Senior Vice President and Chief Accounting Officer, will succeed Mr. Hedges as CFO, effective January 1, 2023.

12:13 EST Timber Pharmaceuticals announces 1-for-50 reverse stock split - Timber Pharmaceuticals announced that it will effect a 1-for-50 reverse stock split of its outstanding common stock. Subject to NYSE American approval, the Company anticipates that trading will resume on the NYSE American on an as-adjusted basis as of the commencement of trading on Wednesday, November 9, 2022. As previously announced, the trading of the Company's shares of common stock was halted by the Exchange due to the low trading price of the Company's shares of common stock on November 1, 2022. Although not anticipated by the Company, the Exchange could maintain the trading halt. The Exchange could also suspend trading and move to delist the Company's common stock if the price per share post-split does not meet the requirements of Section 1003(f)(v) of the NYSE American Company Guide. The reverse stock split will reduce the number of shares of common stock issued and outstanding from approximately 145.5 million to approximately 2.9 million. On November 7, 2022, the holders of a majority of the Company's outstanding shares of common stock and Series B mirroring preferred stock approved the reverse stock split and gave the Company's board of directors discretionary authority to select a ratio for the split ranging from 1-for-25 to 1-for-50. The board of directors approved the reverse stock split at a ratio of 1-for-50.

12:01 EST American Equity falls -16.5% - American Equity is down -16.5%, or -$6.93 to $35.07.

12:00 EST International Game rises 17.0% - International Game is up 17.0%, or $3.40 to $23.34.

12:00 EST Triumph Group rises 29.0% - Triumph Group is up 29.0%, or $2.76 to $12.27.

11:50 EST CoreCard Corp trading halted, volatility trading pause

11:36 EST European Commission opens in-depth investigation into Activision takeover - The European Commission said it has opened an in-depth investigation to assess the proposed acquisition of Activision Blizzard (ATVI) by Microsoft (MSFT) under the EU Merger Regulation. The Commission is concerned that the proposed acquisition "may reduce competition in the markets for the distribution of console and personal computers video games and for PC operating systems." The Commission's preliminary investigation shows that the transaction "may significantly reduce competition on the markets for the distribution of console and PC video games, including multigame subscription services and/or cloud game streaming services, and for PC operating systems." The Commission is concerned that, by acquiring Activision Blizzard, Microsoft may foreclose access to Activision's console and PC video games, especially to "high-profile and highly successful games" such as "Call of Duty."

11:13 EST Bankman-Fried says deal reached for strategic transaction with Binance for FTX - Sam Bankman-Fried, the founder and CEO of FTX, tweeted: "Hey all: I have a few announcements to make. Things have come full circle, and FTX.com's first, and last, investors are the same: we have come to an agreement on a strategic transaction with Binance for FTX.com (pending DD etc.). 2) Our teams are working on clearing out the withdrawal backlog as is. This will clear out liquidity crunches; all assets will be covered 1:1. This is one of the main reasons we've asked Binance to come in. It may take a bit to settle etc. -- we apologize for that. 3) But the important thing is that customers are protected. [...] 5) I know that there have been rumors in media of conflict between our two exchanges, however Binance has shown time and again that they are committed to a more decentralized global economy while working to improve industry relations with regulators. We are in the best of hands." Reference Link

11:03 EST Ionis Pharmaceuticals announces data from GSK's Phase 2b study of bepirovirsen - Ionis Pharmaceuticals (IONS) announced that GSK (GSK) presented positive end of study data from the Phase 2b B-Clear study of bepirovirsen, an investigational antisense oligonucleotide treatment for patients with chronic hepatitis B virus. The results showed that treatment with bepirovirsen resulted in sustained clearance of hepatitis B surface antigen and hepatitis B virus DNA for 24 weeks after end of bepirovirsen treatment in people with CHB. The study results were presented at the American Association for the Study of Liver Diseases' The Liver Meeting in Washington, DC. The results from the B-Clear Phase 2b study provide initial evidence that bepirovirsen, as monotherapy or in combination with nucleoside/nucleotide analogue, can deliver sustained reductions in HBsAg and HBV viral DNA in specific patient groups. The full results from the study are now available in The New England Journal of Medicine. In treatment arm 1 of the study, 9% of patients on NA treatment and 10% of patients not on NA treatment achieved the primary outcome of HBsAg levels below the Lower Limit of Quantification and HBV DNA levels below the LLOQ, respectively. This is defined as a sustained response and was observed for 24 weeks post last dose. In the study, sustained response rates were higher in subjects with low baseline HBsAg than in those with high baseline HBsAg. Patients with low baseline hepatitis B surface antigen levels responded best to treatment with bepirovirsen with 16% and 25% of patients achieving the primary outcome in treatment arm 1 of the on NA and not on NA cohort, respectively. Currently, nucleoside/nucleotide analogues are the recommended first-line therapy for patients with chronic HBV because they can inhibit viral replication. However, they cannot clear the virus and are generally taken for life. Bepirovirsen is uniquely designed to reduce HBV replication and suppress HBsAg and stimulate innate immunity which could potentially lead to functional cure. Functional cure is largely defined as sustained, undetectable levels of HBV DNA and HBsAg in the blood with or without generating protective antibodies after a finite course of treatment. Functional cure occurs when the virus is not eliminated from the body but is at low levels that are undetectable in blood and can be controlled by the immune system without medication. GSK is exploring sequential treatment trials of bepirovirsen with other therapeutic modalities, with the aim of increasing functional cure rate in more patients and reducing the overall burden of CHB. These include Phase 2b study of bepirovirsen in sequential combination with pegylated interferon treatment; Phase 2 study of bepirovirsen in sequential combination with GSK's chronic hepatitis B targeted immunotherapy.

10:47 EST Adtran sees continued supply chain challenges ahead - Comments taken from Q3 earnings conference call.

10:11 EST Fast Radius files Chapter 11 bankruptcy, seeks bids by Dec. 5 - Fast Radius announced overnight that it is launching an in-court process to effectuate one or more strategic transactions and has filed voluntary petitions for relief under Chapter 11 of the United States Bankruptcy Code in the District of Delaware. The company has requested that the court establish certain sale and marketing procedures, which include a proposed bid deadline of December 5. Fast Radius said it is in active discussions with one or more potential partners and continues to explore and evaluate strategic alternatives. Fast Radius will continue to operate its business as a "debtor-in-possession" under the jurisdiction of the bankruptcy court and in accordance with the applicable provisions of the U.S. Bankruptcy Code. The stock in

10:10 EST Jones Soda engages Empire Marketing to grow Kroger partnership - Jones Soda announced that it has engaged the services of food broker Empire Marketing Strategies to expand its existing relationship with Kroger stores. More than 2,000 Kroger-owned stores nationwide currently carry core Jones Soda items, including top-selling flavors in single bottles and multi-packs as well as Jones' rotating series of limited-edition Special Release flavors. Distribution spans all stores operating under the Kroger brand as well as hundreds operating under the Dillon, Fred Meyer, Frys, King Soopers, Ralphs, Roundy's, Smiths and QFC banners. Empire is now responsible for the management of Jones Soda and its sister Lemoncocco brand at the Kroger general office, store and division levels, including efforts to increase Jones' brand assortment in-store across all Kroger divisions.

10:07 EST Helbiz Kitchen enters partnerships with Glovo, Deliveroo - Helbiz announced partnerships between its food preparation and delivery service, Helbiz Kitchen, and two industry leading Italian delivery providers. The first partner is Deliveroo, an Amazon backed company, that is a leader in the Milan food-delivery market. The second partner is Glovo, a Spanish on-demand courier which serves more than 15 million customers across 25 countries and has been active since April 2021. These partnerships greatly expand Helbiz Kitchen's user base, reach, and overall business opportunity in Italy, without compromising the company's high quality service. As part of this agreement, Helbiz Kitchen restaurants - Burger & Sons, Pokaii, Pomodoro, Wabisabi, What the Farm, and La Bottega del Gelato - will be available to order from both apps. The prices for Helbiz Kitchen's dishes will remain unchanged when ordering on either app.

10:04 EST Horizon Therapeutics announces presentation on MIRROR trial data - Horizon Therapeutics announced that Month 12 data from the MIRROR randomized controlled trial of KRYSTEXXA injection with methotrexate will be featured in Plenary I as part of the American College of Rheumatology Convergence 2022. Additional presentations include new imaging analyses describing the effects of urate-lowering therapy on joint health and vascular inflammation for people with chronic gout refractory to conventional therapies, also known as uncontrolled gout. This analysis extends the MIRROR randomized controlled trial body of data through Month 12 of treatment, showing a sustained patient response rate and similar safety profile to the Month 6 findings. Of patients randomized to receive KRYSTEXXA with methotrexate, 60% (60 of 100) achieved serum uric acid level less than 6 mg/dL for at least 80% of of the time during Month 12 treatment versus 30.8% for those randomized to receive KRYSTEXXA with placebo. Of patients with validated tophi at baseline, 53.8% in the KRYSTEXXA with methotrexate group had complete resolution of at least one tophus, no new tophus and no single tophus showing progression at Week 52 compared with 31.0% in the KRYSTEXXA with placebo group. Pharmacokinetic and immunogenicity findings through treatment Month 12 were consistent with Month 6 findings, indicating higher KRYSTEXXA exposure and lower KRYSTEXXA immunogenicity in those who received methotrexate co-therapy. 12-month Findings of the Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase: Imaging studies demonstrate effect of aggressive urate-lowering therapy on urate deposits in the joints and vasculature: An imaging analysis from the MIRROR randomized controlled trial used dual-energy computed tomography to visualize and quantify monosodium urate crystal deposits, which are caused by elevated uric acid levels, in the hands, elbows, feet and knees of participating uncontrolled gout patients at specified timepoints throughout the 52-week treatment period. In total, eight participants were included in the imaging analysis. MSU volume had markedly decreased in both treatment groups at Week 52. These volume reductions were comparable in different regions of the same patients and occurred similarly with sustained urate-lowering in both treatment groups. Reduction in Monosodium Urate Crystal Deposit Volume During the MIRROR RCT Trial in Patients Treated with Pegloticase Plus Methotrexate Co-therapy: A Serial Dual-Energy Computed Tomography Analysis The Mount Sinai Hospital initiated a trial using DECT imaging and fluorodeoxyglucose positron emission tomography combined with computed tomography to quantify the presence of MSU deposits in the vasculature of uncontrolled gout patients and correlate this to vascular inflammation to further understand a possible link between uncontrolled gout and cardiovascular risk. In this analysis, ten patients with uncontrolled gout were treated with co-therapy of an immunomodulator and KRYSTEXXA every two weeks for up to six months. DECT and FDG-PET/CT scans were completed at baseline and after up to six months of treatment to detect vascular MSU deposition and arterial inflammation. The analysis found a statistically significant decrease in arterial inflammation after treatment across all arteries studied and a trend toward a decrease in MSU volume.

10:00 EST MeridianLink falls -19.3% - MeridianLink is down -19.3%, or -$3.12 to $13.02.

10:00 EST Veritiv rises 14.4% - Veritiv is up 14.4%, or $15.62 to $124.42.

10:00 EST Hims & Hers rises 20.1% - Hims & Hers is up 20.1%, or 93c to $5.55.

09:53 EST Ancora supports management transition at Kohl's - Ancora Holdings, the beneficial owner of approximately 2.5% of the outstanding shares of Kohl's, issued the following statement regarding the company's announced management transition: "As outlined in our September 22nd letter to the Kohl's Board of Directors, it is the right time for the company to pivot to a leadership team with enhanced operational expertise and strong turnaround experience. We are very pleased that Kohl's will be appointing retail sector veteran Tom Kingsbury, who was nominated by our shareholder group in 2021, as its interim Chief Executive Officer. We are also pleased that Tom and our group's other designee, Margaret Jenkins, will be part of the new committee tasked with identifying the right permanent leader for the business. Ancora has been a long-term shareholder of Kohl's and believes that under the right leadership, the company can be a source of tremendous value for investors, customers suppliers and employees."

09:48 EST Huadi International Group Co trading halted, volatility trading pause

09:47 EST Clarivate falls -17.8% - Clarivate is down -17.8%, or -$1.77 to $8.18.

09:47 EST Planet Fitness rises 10.3% - Planet Fitness is up 10.3%, or $6.37 to $68.00.

09:47 EST Hims & Hers rises 23.6% - Hims & Hers is up 23.6%, or $1.09 to $5.71.

09:39 EST Bioventus trading resumes

09:34 EST Bioventus trading halted, volatility trading pause

09:30 EST Tactile Systems trading halted, volatility trading pause

09:26 EST SharpLink Gaming announces 2022 Extraordinar General Meeting of Shareholders - SharpLink Gaming announced that it will hold an extraordinary general meeting of shareholders on Monday, December 14, 2022 at 4:00 PM Central Time at SharpLink's corporate office located at 333 Washington Avenue North, Suite 104, Minneapolis, Minnesota 55402, and thereafter as it may be adjourned or postponed from time to time. The primary purpose of the Meeting will be to approve the merger and related transactions with SportsHub Games Network. The agenda of the Meeting is as follows: To approve the consummation of the Transaction contemplated by the Agreement and Plan of Merger, dated September 7, 2022, as amended by the First Amendment to the Agreement and Plan of Merger, dated November 2, 2022. To transact any other business that may be properly brought before the Meeting or any continuation, adjournment or postponement thereof. Shareholders of record at the close of business on Monday, November 14, 2022 are entitled to notice of and to vote at the Meeting or any adjournments or postponements thereof. The Company plans to mail the proxy statement and a proxy card on or about Friday, November 18, 2022. The approval of the proposal submitted to shareholders requires the affirmative vote of holders of at least a majority of the Company's Ordinary Shares represented at the Meeting, in person or by proxy, entitled to vote and voting on the matters presented for passage, as well as the support of the special majority as more fully described in the proxy statement.

09:23 EST Performance Shipping announces $32,000 per day time charter contract - Performance Shipping (PSHG) announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with ST Shipping & Transport, a wholly-owned subsidiary of Glencore (GLNCY), for the M/T Phoenix Beacon. The acquisition of the vessel, to be renamed M/T P. Monterey, was previously announced. The gross charter rate will be US$32,000 per day for a period of twenty-four months +/- 45 days at the option of the Charterer and will commence following the vessel's delivery to the Company in December. This charter is expected to generate approximately US$22 million of gross revenue for the minimum duration of the charter. The M/T P. Monterey is a 105,525 dwt Aframax tanker vessel built in 2011 by Hyundai Heavy Industries Co., Ltd. - Ulsan, South Korea. Commenting on this charter, Andreas Michalopoulos, the Company's Chief Executive Officer, stated: "We are very pleased to announce that upon delivery of our newly acquired tanker in December, the M/T P. Monterey will commence service under a new time charter contract with a reputable counterparty and at a lucrative charter rate. Upon commencement of this charter, more than half of our expanded fleet will be under time charter contracts resulting in fixed revenues of approximately US$68 million, based on the minimum durations, representing 4.2x our current equity market capitalization."

09:22 EST Novavax says data show no benefit for bivalent vaccine compared to BA.1 vaccine - Novavax announced earlier topline results from its Phase 3 Boosting Trial for the SARS-CoV-2 rS Variant Vaccines showing that the company's BA.1 vaccine candidate, NVX-CoV2515, met the primary strain-change endpoint. "The data demonstrate that the BA.1 vaccine candidate neutralizing responses in those not previously exposed to COVID-19 were greater than those of the prototype vaccine, NVX-CoV2373, enabling a shift to a new variant vaccine, if necessary. Additionally, data show no benefit for the Novavax bivalent vaccine candidate compared to the BA.1 vaccine candidate or prototype vaccine in the overall trial population. Immunoglobulin G antibody responses against BA.1 and prototype strains showed similar responses across the three vaccine groups. Importantly, for the BA.5 strain, which is structurally similar to BA.1, pseudoneutralization responses demonstrated that there was no benefit for the BA.1 or bivalent vaccine candidates compared to the prototype vaccine. Overall, the data demonstrated that the prototype vaccine induced a broad immune response against original prototype, BA.1, and BA.5 strains. The prototype vaccine induced robust IgG responses to both BA.1 and the matched prototype strain. Pseudoneutralization responses against BA.5 for the prototype vaccine were comparable to those induced by the more closely matched BA.1 vaccine and bivalent vaccine candidates... When given as a second booster dose, or fourth dose, all three vaccine formulations were similarly well-tolerated, consistent with the well-established safety profile of the prototype vaccine," the company stated. "Today's results show that use of our prototype vaccine as a booster induces cross-reactive responses to a broad range of variants with the potential to protect against future strains. This is a hallmark of our vaccine technology and shows the suitability of our current prototype vaccine as a booster even as the COVID-19 landscape continues to evolve. Our vaccine, which provides broad immune response even in the face of evolving variants, presents a potential strategy to protect against COVID-19 now and into the future," said Gregory M. Glenn, M.D., President of Research and Development, Novavax.

09:20 EST Galecto expects cash to fund requirements into 2H24 - Cash, cash equivalents, and investments as of September 30, 2022 were approximately $75.9 million. The Company anticipates that its cash, cash equivalents and investments will be sufficient to fund operating expenses and capital requirements into the second half of 2024.

09:15 EST Lexaria Bioscience begins DIAB-A22-1 study - Lexaria Bioscience announced that study program DIAB-A22-1 is expected to begin on schedule. This is Lexaria's first-ever study to investigate whether its patented DehydraTECH-processed cannabidiol, or CBD, may potentially have therapeutic utility against diabetes. Lexaria has previously evidenced the safety and efficacy of DehydraTECH-CBD in human hypertension studies.

09:11 EST Verizon expands relationship with MiCTA - Verizon Public Sector and the Michigan Collegiate Telecommunications Association, MiCTA, a national nonprofit organization that serves more than 8,000 members in higher education, K-12, health care, library, governmental and charitable entities, have expanded their relationship to enable MiCTA members to more easily and efficiently access Verizon's comprehensive suite of communications solutions. Nationally, MiCTA negotiates discounted purchase contracts for telecommunications and technology services, provides legislative advocacy and information support for its members. The expansion of the Verizon Public Sector agreement will help MiCTA's members modernize their communications infrastructure. "The nation's state, local government agencies and educational institutions deserve every advantage when it comes to improving citizen engagement and experience and enabling students to stay connected," said Patty Roze, Vice President of SLED for Verizon Public Sector. "When MiCTA members have access to the nation's most reliable 5G network, cutting-edge technologies and improved security solutions, there are huge benefits to the communities that MiCTA's members serve."

09:10 EST Backblaze launches new partner program - Backblaze announced the launch of a new partner program for resellers, integrators, managed service providers, and more. The new program includes a self-service portal, reserve pricing, dedicated support, and additional resources. The program provides new opportunities to four key partner groups: Channel Partners; Technology Partners; Managed Service Providers: and Affiliates. "Ease of use and accessibility can have a significant impact for our partners and their business," said Nilay Patel, Backblaze Vice President of Sales. "We are continuously looking for ways to innovate and develop for our partners. Offering this easy, accessible and efficient resource will strengthen our relationship with our customers."

09:08 EST CareCloud's electronic health record solutions earn latest ONC certification - CareCloud announced it has achieved Office of the National Coordinator for Health Information Technology, ONC, certification for its electronic health record, EHR, solutions, VertexDR and talkEHR, and they are now compliant with 21st Century Cures Act Final Rule requirements. "While CareCloud's EHR systems easily integrate with other CareCloud products, it's also important for them to communicate easily with other EHR systems to ensure patient information can be securely shared when needed," said CareCloud Chief Technology Officer Adeel Sarwar. "Since not all healthcare providers use the same EHR platform, the data stored in each EHR must be easily transmittable to other EHRs to ensure the exchange of information. Our goal is to help providers transition into the new generation of healthcare, which means providing products and services with information that is easily accessible, adheres to HIPAA standards and helps providers improve health outcomes through value-based care."

09:06 EST Senmiao Technology reports October orders up 71,6% from September - Senmiao Technology announced the operating metrics for its proprietary online ride-hailing platform for the month of October. In October, Senmiao and its affiliates reported over 900,000 total completed orders, a 71.6% increase from over 500,000 total orders completed in September 2022, as a result of online ride-hailing service restrictions being lifted following their suspension in Chengdu in the first half of September 2022.

09:05 EST DuPont approves new $5B share buyback program, plans accelerated share buyback - DuPont's board of directors has approved a new share repurchase program authorizing the repurchase and retirement of up to $5B of common stock. This new repurchase authorization is in addition to the $250M remaining under the company's existing share repurchase program which was approved in February 2022. The company intends to enter accelerated share repurchase agreements, or "ASR Agreements," imminently, for the repurchase of an aggregate of approximately $3.25B of common stock with $250M of such repurchases under the existing program and the remaining $3B under the new program. "Any additional repurchases under the new share repurchase program will be made from time to time on the open market at prevailing market prices or in privately negotiated transactions off the market, which may include additional accelerated share repurchase agreements. The timing and number of shares to be repurchased will depend on factors such as the share price, economic and market conditions, and corporate and regulatory requirements. The new repurchase program terminates on June 30, 2024, unless extended or shortened by the Board of Directors. Reflecting DuPont's commitment to a balanced capital allocation framework, the company announced its intent to retire $2.5B of Senior Notes due in November 2023 during the fourth quarter of 2022. This will enable approximately $100M of annual interest savings. Additionally in the fourth quarter, the company plans to reduce its commercial paper balance to zero. As of September 30, 2022, the company had $1.3B of commercial paper outstanding. The new share repurchase program and the intended de-levering actions demonstrate the company's continued commitment to return value to shareholders and in maintaining a strong balance sheet within the framework of its balanced capital allocation policy. In addition, the company's M&A focus remains on bolt-on targets that fit within its key growth pillars and are aligned with secular trends," the company stated.

09:04 EST LiqTech awarded order for wastewater treatment in Denmark - LiqTech International announced the receipt of an order for a wastewater treatment system for the metal processing industry in Denmark. The project will deploy a complete filtration system solution leveraging LiqTech's silicon carbide, or SiC, membrane that has unique technical advantages for treating this type of wastewater. Wastewater from the metal processing industry contains many demanding substances, including lubricating oils, suspended solids, various raw metals, surfactants, corrosion inhibitors, antifoam agents, biocides, and others. From an operational point of view, an efficient treatment of this wastewater will help the industry significantly by reducing water usage and decreasing the costs associated with the handling of polluted water effluent. Also, the use of LiqTech's SiC membrane-based water treatment systems will enable customers to much easier comply with strict environmental regulation of their polluted water effluent.

09:03 EST CN joins the United Nations Global Compact - CN is pleased to announce that it has joined the United Nations Global Compact initiative - a voluntary leadership platform for the development, implementation and disclosure of responsible business practices Launched in 2000, the UN Global Compact is the largest corporate sustainability initiative in the world, with more than 15,000 companies and 3,800 non-business signatories based in over 160 countries, and more than 69 Local Networks.

09:02 EST eXp Realty opens operations in Poland - eXp Realty, the core subsidiary of eXp World Holdings, has expanded into Poland. eXp Realty now operates in 23 markets with more than 86,000 agents around the world. "Poland's rapid growth and continued resilience in the real estate market along with its rich and multi-cultural history, speaks to the attractiveness of its property sector for both foreign and domestic investments and strategically complements our existing European presence, " said Michael Valdes, Chief Growth Officer. "We are changing the way real estate is done around the world and are excited to empower agents in Poland with our unique model built for success."

09:02 EST Sanofi, Insilico Medicine enter strategic research collaboration - Insilico Medicine announced a multi-year, multi-target strategic research collaboration with Sanofi. Under the terms of the agreement, the collaboration will leverage Insilico Medicine's AI platform, Pharma.AI, to advance drug development candidates for up to six new targets. Under the terms of the agreement, Sanofi will pay Insilico Medicine a total of up to $21.5 million covering the upfront and target nomination fees to benefit from Insilico's end-to-end Pharma.AI platform and gain access to a team of interdisciplinary drug discovery scientists to identify, synthesize, and advance high-quality lead therapeutic compounds up to development candidate stage. Additional payments will be made if key research, development, and sales milestones are met, and could total up to $1.2 billion. The collaboration also establishes mid-single to up to low double-digit tiered royalties for any products developed.

09:00 EST Lexicon to present final results from Phase 2 RELIEF-DPN-1 trial of LX9211 - Lexicon Pharmaceuticals announced that the final results from the Phase 2 RELIEF-DPN-1 trial of its investigational drug LX9211, a novel, highly selective inhibitor of adaptor-associated kinase 1, will be presented during a podium presentation at the 16th Annual Pain Therapeutics Summit in Washington, D.C. The presentation will be given by Anand Patel, M.D., the Chief Medical Officer at Conquest Research and a principal investigator in the RELIEF-DPN-1 study, on November 14th at 3:35pm ET, and is entitled: "A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of LX9211 in the Treatment of Diabetic Peripheral Neuropathic Pain." The presentation will describe the preclinical basis for the program, the framework of the trial, and an analysis of the final results from this successful proof-of-concept study. Following the presentation, Dr. Patel will join Lexicon management on a live conference call and webcast at 5:00pm ET to discuss the study results. RELIEF-DPN-1 was a Phase 2 randomized, double-blind, placebo-controlled, parallel-group, multicenter study evaluating the efficacy, safety and pharmacokinetics of LX9211 in the treatment of painful diabetic neuropathy, also referred to as diabetic peripheral neuropathic pain. The study enrolled 319 patients at 45 U.S. clinical sites, evaluating three treatment groups receiving placebo or one of two dosing regimens of LX9211. The primary efficacy endpoint under evaluation was the change from baseline to week 6 in ADPS, based on the 11-point numerical rating scale. The results of the study on the primary endpoint showed a reduction from baseline in ADPS of 1.39 points in the low dose arm and 1.27 points in the high dose arm, compared to 0.72 in the placebo arm. Under the statistical analysis plan for the study, a p-value of less than 0.028 was considered statistically significant. The RELIEF-DPN-1 study was the first of two Phase 2 proof-of-concept studies evaluating LX9211 in neuropathic pain. LX9211 is also under evaluation in RELIEF-PHN-1, a study in patients with post-herpetic neuralgia, from which Lexicon is targeting top-line results around the end of the fourth quarter of 2022.

08:57 EST Johnson Controls signs new project with Canada's Department of National Defence - Johnson Controls has secured its fifth project with Canada's Department of National Defence in support of the DND's 2050 Net Zero Goals. The efficiency initiative at 2nd Canadian Division Support Base, or CDSB, Valcartier is designed to reduce greenhouse gas emissions by 58% during the length of the 14-year contract and energy costs by CA$1.5M annually. This project brings the Canadian DND's total projected energy cost savings generated in collaboration with Johnson Controls to CA$8.2M annually, as well as a combined 37,000-ton reduction in GHG emissions per year. Previous collaborations between Johnson Controls and Canada's DND include CFB Bagotville, CFB Petawawa, CFB Kingston and CFB Halifax.

08:55 EST Avalon Globocare Corp trading halted, news pending

08:53 EST Sodexo, Southern Connecticut State, Adam Equipment reduce dining hall waste - Sodexo in partnership with Southern Connecticut State University's Office of Sustainability and scale manufacturer Adam Equipment, announced today the Weigh the Waste event in honor of Sodexo's WasteLESS week. The event, which took place on October 24 - 28, encouraged students on SCSU's campus to monitor and minimize their carbon footprint in the dining hall. During the one-week event, students scraped their unwanted food remains into a large container in the dining hall which sat atop Adam Equipment's GFK 330a, a floor checkweighing scale. GFK features a large 15.7" by 19.7" stainless steel platform, allowing Sodexo foodservice workers to place a container on the platform for convenient weighing of up to 330 lbs. of food. The scale remained on during the entire event, allowing students to see in real-time the increase in weight with each plate. By the end of the week, the dining hall collected more than 1,700 lbs of food waste, which will be composted.

08:51 EST Omeros says FDA decision on resolution denies appeal request for immediate talks - Omeros announced that the Office of New Drugs OND of the U.S. Food and Drug Administration FDA has reached a decision on the company's formal dispute resolution request appealing the issuance by FDA's Office of Cardiology, Hematology, Endocrinology and Nephrology and the Division of Nonmalignant Hematology of a complete response letter or CRL, concerning the biologics license application BLA, for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy, TA-TMA. In its formal dispute resolution request submitted to the Agency in June , Omeros requested OND to direct the review division to accept resubmission of the existing BLA and to commence labeling discussions with the company immediately thereafter. Although that request was denied, the decision proposes a path forward for the resubmission of the BLA based on survival data from the completed pivotal trial versus an historical control group. Specifically, the decision proposes the resubmission of the narsoplimab BLA including a comparison of the existing response data from the completed pivotal trial to a threshold derived from an independent literature analysis and evidence of increased survival from patients in the pivotal trial compared to an appropriate historical control group. It also notes that persuasive evidence of superior survival versus a well-matched historical control group could be sufficient even in the absence of the independent literature analysis. The specific approach to resubmission and its details would be determined through discussion with the review division. Omeros is currently working through the details of the decision and potential next steps with its team of regulatory and legal advisors and will discuss this development further on its previously announced earnings call scheduled for tomorrow, November 9, 2022. "While this decision does not allow us to begin labeling discussions now, it does provide paths forward based on collecting historical data with or without an independent literature review," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "There currently is no approved treatment for TA-TMA, and transplant physicians and their patients need one. We look forward to working with the Agency to obtain approval for narsoplimab as soon as possible."

08:50 EST Altamira Therapeutics announces data published in journal on its Bentrio - Altamira Therapeutics announced that the International Archives of Allergy and Immunology has published a peer-reviewed article titled, "Efficacy and safety of a drug-free, barrier-forming nasal spray for allergic rhinitis: randomized, open-label, crossover noninferiority trial." The trial showed that Bentrio alleviated allergic nasal symptoms during controlled exposure to grass pollen for four hours. Compared to a marketed nasal spray based on hydroxypropylmethylcellulose powder, Bentrio showed non-inferiority with faster onset of action and superior global efficacy ratings by study participants and clinicians. The treatment was safe and well tolerated. The results from the trial provided essential clinical data for obtaining market clearance by the US Food and Drug Administration, which occurred in June 2022. "We're pleased to see details about this exciting study published following peer review," said Jean Lachance, Head of Altamira Therapeutics' OTC Consumer Health Business Unit. "Bentrio showed a persisting protective effect over the four hours of pollen exposure, which was in line with the other tested barrier-forming nasal spray. We were very pleased by the more rapid onset of protection, which we believe was a major factor driving the superior overall rating of efficacy by patients and investigators. With this study we had initiated the clinical testing of Bentrio, which since then has greatly expanded," Lachance added. "Earlier this year, we announced positive outcomes also under house dust mite challenge, and our large NASAR trial with sufferers from seasonal allergic rhinitis in Australia is progressing towards an expected read-out in the first half of 2023. At the same time, we are looking forward to seeing the results from our COVAMID trial with Bentrio in acute COVID-19, which are expected later in the current fourth quarter."

08:48 EST 9 Meters Biopharma expects cash to fund programs into 2H23 - As of September 30, 2022, the Company's cash and cash equivalents totaled approximately $39.4 million, of which $23.5 million was restricted cash, compared to cash and cash equivalents of approximately $29.5 million as of June 30, 2022. The Company anticipates that its cash runway is sufficient to fund the ongoing clinical programs into the second half of 2023.

08:44 EST ART adjusts pricing to reflect higher input costs - Advanced Refining Technologies, ART, the joint venture of U.S. specialty chemicals and materials company W. R. Grace & Co. and U.S.-based energy company Chevron, announced global price increases for its hydroprocessing catalysts amid rapidly rising raw materials and energy costs. Prices will increase up to 15% based on product type and specific customer commitments. "The demand for high-quality hydroprocessing catalyst technology remains extremely high as demand and margins for refined products continue to strengthen through the end of 2022 and into 2023," said Nathan Ergonul, ART Managing Director. "The pricing actions we are taking today are necessary to offset record inflationary pressure while continuing our commitment to offering industry-leading catalyst performance and expert-level technical service. These actions are essential to continue creating significant incremental profit for our customers."

08:43 EST Skeena Resources announces drilling results from Eskay Creek Project - Skeena Resources is pleased to announce additional drilling results from the 21A West Zone delineation program as part of the recently completed 2022 regional and near mine exploration campaigns at the Eskay Creek gold-silver Project in the Golden Triangle of British Columbia. Exploratory drill hole SK-22-1122 intersected high tenor gold and silver mineralization in Rhyolite facies rocks below the Contact Mudstone, averaging 20.43 g/t Au, 175.2 g/t Ag over 24.00 m with many notable high-grade subintervals including 80.20 g/t Au, 2,790.0 g/t Ag over 0.50 m and 65.80 g/t Au, 1.1 g/t Ag over 0.93 m. This drill hole has expanded and predictably validated the geometry of the evolving 21A West Zone discovered in late 2021 and is situated 15 metres vertically below previously reported 2022 drill hole SK-22-1093, which intersected 47.50 g/t Au, 73.4 g/t Ag over 12.12 m. The 21A West Zone remains open for expansion both down-dip and along strike. Occurring within the intended open-pit at a vertical depth of only 60 metres below surface, this area of the resource was never populated by previous drilling and as such was previously modelled as barren waste rock. New Rhyolite-hosted mineralization has also been intersected by exploratory drill hole SK-22-1095 grading 5.39 g/t Au, 10.9 g/t Ag over 20.60 m including 26.80 g/t Au, 12.6 g/t Ag over 0.74 m and 22.20 g/t Au, 8.1 g/t Ag over 1.10 m. This new occurrence is situated 25 metres below the currently planned open-pit and remains open for expansion. A total of 55,652 metres were drilled over 215 holes during the 2022 drilling program and will be incorporated into the H2 2023 Resource update.

08:42 EST Blue Water appoints Jeremi to board of directors - Blue Water Vaccines announced the appointment of seasoned advisor and executive, Vuk Jeremi, to the Company's board of directors. Currently, Jeremi is the President of the Center for International Relations and Sustainable Development.

08:41 EST Sigma Additive Solutions in pact with SLM Solutions to enhance integration - Sigma Additive Solutions announced that its PrintRite3D in-process quality assurance solution will be certified as PrintRite3D Ready to work with SLM's industrial metal additive manufacturing, or AM, machines. The objective of the integration is for the companies to utilize SLM's open architecture and SLM.Quality APIs to enable the integration of PrintRite3D, Sigma's third-party agnostic quality assurance software and analytics solution.

08:41 EST Processa Pharmaceuticals announces results from its PCS12852 Phase 2A trial - Processa Pharmaceuticals announces positive gastric emptying results from its PCS12852 Phase 2A trial in patients with moderate to severe gastroparesis. This Phase 2A trial was a 4-week placebo-controlled, randomized, dose-response trial designed to evaluate the effect of PCS12852 on gastric emptying, safety, pharmacokinetics, and gastroparesis symptoms. Two dosage regimens of PCS12852 versus placebo were evaluated in patients with moderate to severe gastroparesis. PCS12852 is a novel, potent, and highly selective 5-hydroxytryptamine-4 receptor agonist. PCS12852 has been shown in normal healthy volunteers and constipation patients to increase GI function with no cardiovascular and no serious adverse effects. Adverse events associated with this Phase 2A trial were mild to moderate, occurring within the first few days after starting treatment, and quickly resolved without any sequelae. GEBT results from this small Phase 2A Proof-of-Concept study, which included a total of 14 patients in the 0.5 mg and placebo groups, demonstrated statistical improvement in gastric emptying in patients receiving 0.5 mg of PCS12852 as compared to placebo at a p less than 0.10 level. . Differences were not observed between the placebo and the 0.1 mg dose.

08:37 EST Avenue Therapeutics completes acquisition of Baergic Bio - Avenue Therapeutics (ATXI) announced the closing of the acquisition of Baergic Bio, pursuant to the previously disclosed Share Contribution Agreement with its parent company, Fortress Biotech (FBIO). Alexandra MacLean, M.D., Chief Executive Officer of Avenue, said, "The acquisition of Baergic Bio is a step forward in our plan to build Avenue into a leader in the development of drugs targeting unmet needs in the CNS field. BAER-101 has the potential to address various orphan indications as well as larger markets with a favorable profile relative to current therapeutic options. Combined with our recent capital raise and potential regulatory path forward for IV tramadol, we believe Avenue has the foundational portfolio to continue to deliver and expand meaningful therapies for patients with CNS diseases."

08:35 EST Delek US sees $75M-$100M of additional share repurchases in Q4 - Delek US, along with announcing financial results for its third quarter last night, stated: "During the third quarter 2022, Delek US repurchased approximately 1.4M shares of Delek US common stock for approximately $40M, with an average price of $27.86 per share. The company expects additional repurchases of approximately $75M-$100M of Delek US common stock during the fourth quarter 2022. Additionally, during the fourth quarter 2022, the company expects to retire approximately $100M-$150M of debt."

08:35 EST VivoPower's Tembo entesr agreement so supply EV conversion kits to Mauritius - VivoPower International announces that the Company and its wholly-owned subsidiary, Tembo e-LV B.V., have entered into a Definitive Distribution Agreement with Energy Trading Company Mauritius to sell, distribute and market Tembo electrification conversion kits for Toyota 4x4 second-hand vehicles in the Republic of Kenya. Under the agreement, ETC Mauritius has committed to sell a minimum of 4,000 Tembo e-LV conversion kits from execution of this agreement until 31st December 2027 across various industry sectors in Kenya. ETC Mauritius will be responsible for acquiring Toyota second-hand vehicles, converting the vehicles to ruggedised e-LVs using Tembo solutions, selling the units to end-customers and providing after-sale servicing and maintenance with support from Tembo. Kevin Chin, Executive Chairman and CEO of VivoPower, said: "We are delighted to announce this distribution partnership with ETC, given their longstanding and deep ties with both government and the private sector in Kenya. This partnership is a landmark milestone for Tembo e-LV on two fronts: it represents our single largest commitment of future orders for Tembo e-LV conversion kits at all levels within a single country and importantly it heralds our entry into the second-hand vehicle repowering market, which effectively multiplies our total addressable market. We look forward to working closely with the ETC team to deliver our solutions to Kenya, assisting both government and private sector achieve their energy transition goals over the next five years and beyond."

08:32 EST Ivanhoe Electric confirms East Ridge discovery at Santa Cruz Copper Project - Ivanhoe Electric Chairman and Chief Executive Officer Robert Friedland is pleased to announce the discovery of the East Ridge oxide copper zone at the Santa Cruz Copper Project, located west of Casa Grande, Arizona. These exploration results have demonstrated the effectiveness of Ivanhoe Electric's proprietary Typhoon surveying system for identifying hidden copper deposits in the American Southwest. In addition, we are beginning to receive high-grade copper assay results from the extensive drilling campaign in the Santa Cruz Deposit area. These results will be incorporated into the updated Mineral Resource Estimate for the Santa Cruz Project expected in January 2023. Mr. Friedland commented: "The discovery of copper mineralization at East Ridge is exciting in that it appears to be open for expansion in all directions. This area, identified by our Typhoon(TM) surveying system, and backed by detailed geological analysis, has proven the effectiveness of our ability to discover new copper deposits in areas hidden under gravel cover within the Basin and Range Province of the Western United States. In addition, the results from our drill campaign at Santa Cruz have confirmed the spectacular grade of the known Santa Cruz Deposit. With the steady pace of new information being received from our work at Santa Cruz, we are increasing our understanding of this enriched copper deposit. Using our Typhoon technology, and now with the knowledge of the Santa Cruz 'fingerprint', we are encouraged by the prospect of additional copper discoveries in the area."

08:23 EST Akari Therapeutics appoints Neylan as EVP, Chief Medical Officer - Akari Therapeutics announced the appointment of John Neylan, III, MD, as Executive Vice President, EVP, Chief Medical Officer, effective today. Dr. Neylan has more than 20 years of experience in medical, clinical development, and R&D. Before joining Akari, he was Executive Vice President, Chief Medical Officer and Head of Research for Angion Biomedica Corporation.

08:21 EST AgileThought expands in South America with new office in Argentina - AgileThought announced the opening of its Argentina office as part of their international expansion strategy. Located in Buenos Aires, Argentina in the heart of the business district, this office will serve the growing employee base in Argentina and enable AgileThought to leverage the diverse talent pool Argentina has to offer. Chief Delivery Officer and Chief Technology Officer for AgileThought, Alejandro Manzocchi added, "Our commitment to developing Delivery Centers around the world where our AgileThought professionals can come together to build connections, learn new technologies and create value for our clients are key components to building relationships and developing digital solutions." Manzocchi goes on to say, "We've received tremendous support and excitement from our employees and clients with this expansion and consider this the first of many steps as we increase our presence in future international markets."

08:19 EST Oxford Lane estimates NAV per share $4.74-$4.84 as of October 31 - Management's unaudited estimate of the range of the NAV per share of our common stock as of October 31, 2022 is between $4.74 and $4.84. This estimate is not a comprehensive statement of our financial condition or results for the month ended October 31, 2022. This estimate did not undergo the Company's typical quarter-end financial closing procedures and was not approved by the Company's board of directors. We advise you that our NAV per share for the quarter ending December 31, 2022 may differ materially from this estimate, which is given only as of October 31, 2022. As of October 31, 2022, the Company had approximately 159.2 million shares of common stock issued and outstanding.

08:17 EST Achieve Life achieves early completion of target enrollment in ORCA-V1 trial - Achieve Life Sciences announced that target enrollment has been reached in the Phase 2 ORCA-V1 clinical trial. ORCA-V1 is evaluating the efficacy and safety of cytisinicline in adult users of nicotine e-cigarettes or vapes. The study enrolled subjects who only used nicotine e-cigarettes, were not currently smoking combustible cigarettes, and who wanted to quit their vaping nicotine dependance. The randomized, placebo-controlled trial will treat 150 subjects in a 2:1 ratio to receive either cytisinicline, dosed at 3 mg three times daily, or placebo, for a period of 12 weeks. Subjects were stratified by prior smoking history. All subjects are receiving standardized behavioral support throughout the trial. The primary outcome will be continuous vaping abstinence during the final 4 weeks of treatment. ORCA-V1 is being supported by the National Institute on Drug Abuse of the National Institutes of Health through grant funding. "The earlier-than-expected completion of enrollment in the ORCA-V1 trial further elucidates the critical need for treatment options specific for nicotine vape users who are interested in quitting," stated John Bencich, Chief Executive Officer of Achieve. "In our previous trials, cytisinicline demonstrated a clear smoking cessation benefit compared to placebo and a very well tolerated safety profile, which we anticipate will apply to vaping cessation and treating nicotine dependence more broadly. We look forward to reporting topline results from ORCA-V1 in the first half of next year."

08:16 EST Zscaler expands partnership with Zoom, announces new integration - Zscaler (ZS) announced new integrations with Zoom Video Communications (ZM) that connect the Zscaler Digital Experience, ZDX, monitoring service with Zoom's Quality of Service Subscription, QSS, offering. The integrated solution gives enterprises' IT and helpdesk teams near real-time quality performance metrics and analytics for all remote office employees. "The number of user-reported quality issues has increased as more hybrid workers rely on Zoom to stay connected and productive. This has put additional strain on Operations Teams including NetworkOps, ITOps, and Service Desk teams, who are expected to respond in real-time," said Dhawal Sharma, Vice President and General Manager at Zscaler. "The new integrations with Zoom augment our existing integrations with Zoom APIs to provide IT and helpdesk teams with granular and real-time insights based on device, network, and application performance that quickly expose the root cause of user experience and reduces Mean Time to Resolution for user-reported issues."

08:15 EST Mobilicom appoints Udi Altshuler as GM of Mobilicom Israel - Mobilicom has appointed Udi Altshuler as Mobilicom's General Manager of its wholly-owned subsidiary Mobilicom Israel. He was most recently Chief Operating Officer of GuardKnox, the automotive industry's first cybertech tier supplier to OEMs and has held senior leadership roles in several global defense technology companies including Elbit Systems, RADA Electronic Industries, BVR Systems, and Cyberbit.

08:13 EST SomaLogic partners with Molecular Genomics for SomaScan Assay - SomaLogic announced that Singapore-based Molecular Genomics, a Genomax Technologies company, will be the first site in Asia to offer the 7,000-plex SomaScan Assay and provide SomaScan data to their customers.

08:12 EST Correction: ATI Physical Therapy appoints Arik Kantz as Chief Legal Officer - ATI Physical Therapy announced that Erik Kantz has been promoted to the role of Chief Legal Officer and Corporate Secretary. Kantz has served as Vice President and Deputy General Counsel for the Company since 2019. Kantz came to ATI in 2016 as Assistant General Counsel Mergers & Acquisitions. Prior to that, Kantz was a partner and Vice Chair of the Business Group at Saul Ewing Arnstein & Lehr, and was previously partner and Director of Operations at College Sports Chicago. He holds a bachelor's degree from Illinois Wesleyan University and a juris doctor degree from DePaul University.

08:10 EST Artelo Biosciences expects cash to fund operations through 1H24 - As of September 30, 2022, the Company had approximately $19.5 million in cash and investments, compared to $25.6 million as of December 31, 2021.

08:08 EST Heska sees FY22 revenue in line with FY22 and up 5% - The company said, "This year's challenges in foreign exchange, inflation, interest rates, labor constraints, supply chain, pandemic-era comparisons, pet patient visit trends, delayed regulatory approvals, and the slower-than-expected launch of truRapid single use tests and Element AIM into Europe and other channels have all combined into headwinds to reaching our 2022 Outlook. We are updating our 2022 Updated Outlook to reflect the accumulation of these factors year to date: reported revenue approximately in line with the prior year and up approximately 5% in constant currency; North America POC Lab Consumables revenue growth rate of approximately 8%-10% vs prior year; international POC Lab Consumables revenue decline of 11%-13% vs prior year on a reported basis, roughly in line with prior year on a constant currency basis. Gross margin of 43%-44% and adjusted EBITDA margin at approximately 11%."

08:05 EST Black Diamond Therapeutics expects cash to fund requirements into 3Q24 - Black Diamond ended the third quarter of 2022 with approximately $144.2 million in cash, cash equivalents, and investments compared to $209.8 million as of December 31, 2021. Net cash used in operations was $16.5 million for the third quarter of 2022 compared to $26.5 million for the third quarter of 2021.

08:04 EST Peloton, Echelon announce settlement of all pending litigation - Peloton and Echelon announce the settlement of all pending litigation between them. All pending actions will be dismissed. As a result of this global settlement, Echelon has agreed that it will cease using Peloton's patented leaderboard technology in on-demand classes. The parties are pleased to put the litigation behind them and will have no further comment.

08:00 EST First Foundation says president DePillo to leave, CFO Thompson named interim - First Foundation announced that David DePillo, who has served as President of First Foundation and First Foundation Bank since 2015, will step down effective immediately. Chief Financial Officer, Kevin Thompson, has been named Interim President of First Foundation and First Foundation Bank while the bank conducts a comprehensive search for a permanent replacement for this role. Thompson will continue to report to Chief Executive Officer, Scott F. Kavanaugh. "The entire executive management team appreciates the service David has given to First Foundation over the last seven years," said Scott F. Kavanaugh. "His contributions to the bank and his commitment to the execution of strategic initiatives have been meaningful. We wish him well as he pursues his future endeavors."

07:59 EST Revival Gold completes drill program, provides exploration update - Revival Gold announces the successful conclusion of its 2022 drill program at the Beartrack-Arnett Gold Project located in Idaho, USA. During the year, Revival Gold completed 22 core holes for a total of about 5,500 meters. Revival Gold's exploration activities will now turn to the review and interpretation of drilling results, updating the Beartrack-Arnett geological and mineral resource models in support of the Company's planned 2023 first phase heap leach Preliminary Feasibility Study, and preparation of plans for future drilling. "Revival Gold's exploration team is to be commended for wrapping up another safe and productive drilling campaign at Beartrack-Arnett this year with exciting results from Joss and the completion of all planned drilling in the Haidee area to support next year's PFS. Further assay results are expected later this month and into the new year, said Hugh Agro, Revival Gold's President & CEO. We look forward to building on 2022's great results in the drilling campaigns to come", Agro added.

07:57 EST Patriot One Technologies chosen to secure Total Mortgage Arena - Patriot One Technologies announced it was chosen to secure entrances to Total Mortgage Arena in Bridgeport, Conn. with its SmartGateway solution, as part of the ongoing partnership between Patriot One and Oak View Group. Patriot One's SmartGateway patron screening solution will be deployed at all entrances to the 10,000-seat Total Mortgage Arena, operated by OVG360. It is home to the New York Islanders' AHL team, the Bridgeport Islanders. As a multi-purpose arena, in addition to sporting events, it also hosts musical acts and touring shows - all of which bring vastly different crowds with different security requirements.

07:56 EST Zai Lab appoints Huang as Chief Scientific Officer - Zai Lab (ZLAB) announced the appointment of Dr. Peter Huang as its Chief Scientific Officer, CSO, effective immediately. Dr. Huang will report to Josh Smiley, Chief Operating Officer of Zai Lab, and will be a key member of the Company's executive committee. He will lead and oversee the Company's discovery efforts and translational medicine. Dr. Huang joins Zai Lab from Zentalis Pharmaceuticals (ZNTL) where he held various roles of increasing responsibility from March 2015 to October 2022. Most recently, Dr. Huang served as Senior Vice President of Discovery Research for Zentalis from October 2020

07:53 EST PyroGenesis announces operational testing results of PUREVAP QRR pilot plant - PyroGenesis Canada confirms, that, further to HPQ Silicon Resources press release of earlier, and further to the Company's news release on October 6, 2022, the Company has successfully completed the high-temperature operational testing phase of the Gen3 PUREVAP Quartz Reduction Reactor pilot plant. An operational test phase, which consisted of a series of optimization and repeatability tests of the production process, were conducted over the past several weeks. The Company announces that the carbon liner substance remained intact, signifying that the system performed beyond expectations. This test included a final continuous operational period of 72 hours at high power. "Advancing the PUREVAP project to this stage has been one of the great achievements of the Company. From initial idea to lab tests, to design and build, and now with the successful operational testing of the pilot plant, our efforts to introduce plasma technology to the high-purity silicon industry is yet another example of how we are putting our scientific and engineering expertise to use in solving some of heavy industry's most pressing issues," said P. Peter Pascali, CEO and Chair of PyroGenesis. "As we have stated before, we firmly believe that the PUREVAP process will prove to be a game changer in the production of a metal as strategically important to future energy goals as silicon. We are proud to be on this journey together with HPQ."

07:53 EST Helius Medical announces participation of OHSU in Therapeutic Experience program - Helius Medical Technologies announced the addition of Oregon Health & Science University to its Therapeutic Experience Program. This initiative will be led by Vijayshree Yadav, MD, MCR, FANA, FAAN, Professor of Neurology and OHSU Multiple Sclerosis Center Director. OHSU joins several other Centers of Excellence in this company-sponsored open-label observational trial designed to evaluate the impact of subjects' adherence to Portable Neuromodulation Stimulator therapy in patients with multiple sclerosis.

07:50 EST Weenit Nano receives silicon wafers from SkyWater Technology - Weebit Nano Limited and SkyWater Technology announce the first silicon wafers integrating Weebit's embedded Resistive Random-Access Memory module have been delivered to Weebit from SkyWater's U.S. production fab. This is the first time silicon wafers of Weebit ReRAM have been received from a production fab, a major milestone toward commercialization of the technology at SkyWater. Manufacturing of Weebit ReRAM is now proven with standard tools and a mature process flow, making it easy for customers to adopt this innovative non-volatile memory for development of their system-on-chip designs. The silicon wafers will be sliced into chips, packaged, and then tested and qualified. The chips, which were manufactured in SkyWater's 130nm CMOS process, will be used for customer demonstrations, testing and prototyping ahead of commercial orders and volume production, allowing customers to confidently start designing SoCs using these ReRAM modules. SkyWater's 130 nm process has been used reliably for billions of devices made for automotive, industrial and consumer applications. The automotive-grade, extended temperature, mixed-signal CMOS platform is well suited for IoT and edge computing as it enables a combination of both digital and analog circuit performance with embedded NVM for a wide range of SoC architectures.

07:47 EST Southland awarded $596M SR 23 bridge project contract - Southland Holdings announced it has been awarded a $596 million contract to construct a new bridge over the St. Johns River near Jacksonville for the Florida Department of Transportation. The project will be completed by Southland's Transportation segment. The scope of work includes constructing a new four-lane, 1.8-mile bridge over the St. Johns River connecting Clay and St. Johns Counties. The new bridge's vertical clearance will be twenty feet higher from the water than the existing bridge, which will improve marine commerce in the region. Also included in the scope is the removal of the existing bridge after the new span opens. Construction is expected to start in 2023.

07:46 EST Instil Bio announces poster presentations of CoSTAR platform - Instil Bio announced poster presentations of pre-clinical data and trial-in-progress for the ongoing ITIL-306 Phase 1 clinical trial using the CoStimulatory Antigen Receptor, CoSTAR, platform at the 37th Annual Meeting of the Society for Immunotherapy of Cancer, SITC, to be held from November 8-12, 2022. Pre-clinical data demonstrating the activity of CoStAR across physiologically-relevant ranges of FRalpha expression and TCR affinity are featured in Poster 282. These data demonstrated that CoStAR amplified T-cell responses at all FRalpha expression levels as long as FRalpha was expressed, supporting the clinical exploration of ITIL-306 in multiple solid tumor types with a variety of FRalpha expression levels. Furthermore, CoStAR-expressing cells do not respond to FRalpha in the absence of TCR stimulation, underscoring the expected safety profile of the CoStAR platform. The company also is presenting a trial-in-progress poster summarizing the design of the ongoing Phase 1 study of ITIL-306. ITIL-306-201 is a Phase 1 multicenter, single-arm, dose escalation and expansion study evaluating the safety and feasibility of ITIL-306 in adult patients with advanced epithelial ovarian cancer, non-small cell lung cancer, and renal cell carcinoma who relapsed from or are refractory to greater than or equal to prior line of systemic therapy. Importantly, the Phase 1 study of ITIL-306 features a treatment regimen free of high-dose interleukin-2.

07:42 EST Ocugen expects funds to enable operations into 4Q23 - The Company's cash, cash equivalents, and restricted cash totaled $101.6 million as of September 30, 2022, compared to $95.1 million as of December 31, 2021. The Company believes that its current cash and cash equivalents balance will enable it to fund its operations into Q4 2023. The Company had 216.7 million shares of common stock outstanding as of September 30, 2022.

07:40 EST CNH Industrial sees 2022 Industrial Activities net sales up 16%-18% - The Company is updating the 2022 outlook for its Industrial Activities: Net sales up between 16% and 18% year on year including currency translation effects; SG&A expenses lower than 7.5% of net sales; Free Cash Flow of Industrial Activities in excess of $1.0 billion; R&D expenses and capital expenditures at around $1.4 billion

07:36 EST Norwegian Cruise Line expects to report net loss for Q4 - As a result of the COVID-19 pandemic, the effects of the Russia-Ukraine conflict and current macroeconomic conditions, while the Company cannot estimate the impact on its business, financial condition or near- or longer-term financial or operational results with certainty, it will report a net loss for the fourth quarter of 2022. The Company does not provide certain estimated future results on a GAAP basis because the Company is unable to predict, with reasonable certainty, the future movement of foreign exchange rates or the future impact of certain gains and charges. These items are uncertain and will depend on several factors, including industry conditions, and could be material to the Company's results computed in accordance with GAAP.

07:36 EST Essential Utilities says Jeanne Russo joins as VP communications ,Nair as CIO - Essential Utilities announced the appointment of two new members to the company's executive leadership team: Jeanne Russo joins the company as vice president, communications, and Sumit Nair will assume the role of vice president and chief information officer.

07:35 EST Norwegian Cruise Line expects quarterly Occupancy levels to increase - The company said, "The Company continued its phased ramp-up in the third quarter focusing on maximizing long-term pricing, which resulted in a 17-point improvement in Occupancy to approximately 82%, consistent with previously outlined expectations. The Company continues to expect quarterly Occupancy levels to increase and reach historical levels for the second quarter of 2023. Given fourth quarter Occupancy is typically lower due to seasonality, we expect Occupancy to be in the mid-to-high 80 percent range, but with the gap versus 2019 levels expected to further narrow. Strong ticket pricing and onboard revenue generation resulted in better-than-expected total revenue per Passenger Cruise Day which was up approximately 14% in the third quarter of 2022 versus 2019, higher than guidance for a high-single digits increase and despite the impact of the Russia-Ukraine conflict on premium-priced Baltic itineraries. For the fourth quarter of 2022, the Company expects total revenue per Passenger Cruise Day to increase approximately 20% versus 2019. The Company reached another significant financial inflection point by generating positive Adjusted EBITDA of approximately $28 million for the third quarter of 2022. The Company continues to target positive Adjusted Free Cash Flow for the fourth quarter of 2022 and slightly positive Adjusted EBITDA for the second half of 2022. In addition, the Company continues to target exceeding historical record Net Yield and Adjusted EBITDA levels for full year 2023 and a return to Adjusted Net Income in 2023."

07:33 EST Norwegian Cruise Line says 2023 booking trends rmain positive - The company said, "As expected, the Company's current cumulative booked position for the fourth quarter of 2022 is below the comparable 2019 period but at higher prices even when including the dilutive impact of future cruise credits. Dilution from value-add FCCs issued during the pandemic will not carry over into 2023 as the bonus portion of these FCCs expire at year-end 2022. Booking trends for full year 2023 remain positive with cumulative booked position equal to record 2019 levels inclusive of the Company's increase in capacity. Pricing is significantly higher than that of 2019 at a similar point in time for full year 2023. Net booking volumes continue to be at the pace needed to reach historical Load Factor levels in 2023. As of September 30, 2022, the Company's advance ticket sales balance, including the long-term portion, was $2.5 billion. This includes approximately $260 million of FCCs or approximately 10% of the total deposit balance. Approximately 60% of the FCC balance outstanding has been applied to future sailings. Gross advance ticket sales build was approximately $1.5 billion during the quarter, in line with the prior quarter."

07:33 EST Yamana enters into arrangement agreement with Pan American, Agnico Eagle - Pan American Silver Corp. (PAAS) and Agnico Eagle Mines Limited (AEM) announced that Yamana Gold Inc. (AUY) has executed and delivered the arrangement agreement providing for the previously announced definitive binding offer dated November 4, 2022 pursuant to which Pan American would acquire all of the issued and outstanding common shares of Yamana and Yamana would sell certain subsidiaries and partnerships which hold Yamana's interests in its Canadian assets to Agnico Eagle, including the Canadian Malartic mine. The Yamana board of directors had previously determined that the Pan American-Agnico Transaction constitutes a "Yamana Superior Proposal" as defined in the arrangement agreement dated May 31, 2022 between Gold Fields Limited (GFI) and Yamana. Yamana entered into the Pan American-Agnico Agreement following receipt of written notice that Gold Fields waived its right-to-match under the Gold Fields Agreement. Gold Fields, however, has not terminated the Gold Fields Agreement and Yamana is not yet legally permitted to do so. The Yamana Board now unanimously recommends that Yamana shareholders vote against the arrangement between Yamana and Gold Fields at the Yamana shareholders' meeting scheduled for 10:00 am on November 21, 2022. The Pan American-Agnico Agreement will become effective only upon the earlier of: (i) the Gold Fields Transaction not being approved at the Yamana Meeting; or (ii) Gold Fields electing to terminate the Gold Fields Agreement. Upon termination of the Gold Fields Agreement by Gold Fields in these circumstances, Yamana will be required to pay a termination fee of US$300 million to Gold Fields within two business days of such termination.

07:31 EST Canada Goose appoints Jess Johannson as chief human resources officer - Canada Goose announced the appointment of Jess Johannson, as chief human resources officer. In this role, she will be responsible for driving the company's human resources strategy across its corporate, manufacturing and retail teams. Johannson will oversee all global teams within HR, including talent acquisition, employee experience, training and global policy. Johannson joins Canada Goose from Tucows, an Internet services and telecommunications company headquartered in Toronto, where she served as chief people officer.

07:30 EST SciSparc announces USPTO granted it a new patent - SciSparc announced that the U.S. Patent and Trademark Office, USPTO, has granted it a new patent - U.S. Patent No. 11,491,172, title: COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS. This patent further strengthens the Company's intellectual property portfolio and protection of its core technologies, and in one of the most important markets in the world. This is SciSparc's seventh granted patent in the United States. Previously, the Company announced it has been granted additional patents in Australia, Japan and Israel. The Company's IP portfolio currently includes nine patent families and two trademarks.

07:29 EST Logiq signs client services contract, expected to generate $2M-$3M per month - Logiq announced that it has recently signed a managed services contract with an undisclosed client that is estimated to generate $2M-$3M in revenue per month going forward. The client, whose name is not disclosed for competitive reasons, is a mid-sized operating business. Commenting, Brent Suen, Chief Executive Officer, said, "We're extremely happy to report the new client win. This contract was already in the new business pipeline of Battle Bridge, a digital marketing firm that we acquired earlier this year. Congratulations go out to our consolidated team that won this contract. This contract speaks to an often-overlooked aspect of our acquisition strategy," Suen continued. "New business leads are not normally valued on a balance sheet, but it is a key component of our due diligence process. By consolidating Battle Bridge with Logiq, major operational synergies were quickly achieved increasing our depth of expertise and expanding the range of services we can offer in-house -- enabling us to better compete for more and larger new business opportunities. Furthermore," he added, "our goal is to provide our new client, and others like them, with access to programmatic advertising to boost their arsenal of advertising and marketing technologies. Our 2021 acquisition of Rebel AI facilitates the on-ramp to ad exchanges for small to medium-sized businesses."

07:24 EST Talkspace appoints Cohen as next CEO - Talkspace announced that it has appointed Dr. Jon Cohen, a board director since September 2022, as its new Chief Executive Officer, CEO. A seasoned executive with extensive experience scaling technology-driven healthcare companies, Dr. Cohen will assume day-to-day leadership of the company from interim CEO Doug Braunstein, who will continue to serve as Chairman of the Board. Cohen brings more than 30 years of healthcare experience. He was previously Executive Chairman and CEO of BioReference Laboratories.

07:21 EST Yamana Gold enters into deal with Agnico and Pan American on acquisition - Yamana Gold (AUY) announced that the Company has entered into an arrangement agreement with Agnico Eagle Mines Limited (AEM) and Pan American Silver Corp. (PAAS) for the acquisition by Pan American of all of the issued and outstanding common shares of the Company and the sale by Yamana of certain subsidiaries and partnerships which hold Yamana's interests in its Canadian assets, including the Canadian Malartic mine, to Agnico, all by way of a proposed plan of arrangement. The terms of the Agnico - Pan American Arrangement Agreement remain the same as previously announced by the Company on November 4, 2022. The Board of Directors of the Company has changed its recommendation with respect to the pending transaction with Gold Fields pursuant to the Gold Fields Arrangement Agreement and now unanimously recommends that Yamana shareholders vote against the Gold Fields Transaction at the special meeting of Yamana shareholders to be held to consider the Gold Fields Transaction. The Yamana Meeting is scheduled to be held at 10:00 am on Monday, November 21, 2022.

07:19 EST ADC Therapeutics says cash runway extends into early 2025 - Cash and cash equivalents were $380.9Mn as of September 30, compared to $376.8M as of June 30. Based on the Company's business plan and expected milestones from Sobi and Healthcare Royalty Partners, the cash runway extends into early 2025. Potential near-term milestone payments from those agreements include a $50 million milestone from Sobi upon European regulatory approval of ZYNLONTA in third-line DLBCL and a $75 million milestone from our HealthCare Royalty Partners agreement for the first EU commercial sale.

07:14 EST Achilles Therapeutics expects cash to fund operations into 2Q25 - Cash and cash equivalents were $179.9 million as of September 30, 2022, as compared to $266.3 million as of December 31, 2021. The impact of translating our books and records from British Pounds Sterling into U.S. dollars had an unfavorable impact on the reported balance cash and cash equivalents. The net decrease reflects an underlying use of $45.7 million for operating and investing activities and a negative $40.7 million foreign exchange impact. The Company anticipates that its cash and cash equivalents are sufficient to fund its planned operations into the second quarter of 2025, including completion of the ongoing Phase I/IIa CHIRON and THETIS clinical trials.

07:12 EST Adidas names Bjorn Gulden as new CEO, effective January 1, 2023 - The Supervisory Board of adidas AG resolved upon the succession for adidas CEO Kasper Rorsted. Effective January 1, 2023, Bjorn Gulden is appointed as member of the Executive Board and CEO of adidas AG. Kasper Rorsted and the Supervisory Board mutually agreed that he will step down as CEO and leave the company upon expiry of November 11, 2022. Harm Ohlmeyer, CFO of adidas AG, will lead the company in the interim until December 31, 2022. The Supervisory Board had announced a CEO transition on August 22, 2022. Gulden has been CEO of Puma SE since 2013. "We are very pleased to welcome Bjorn Gulden back at adidas. Bjorn Gulden brings almost 30 years of experience in the sporting goods and footwear industry. As a result, he knows the industry extremely well and draws on a rich network in sport and retail. Bjorn Gulden already served adidas successfully for seven years in the 1990s. As CEO of Puma, he re-invigorated the brand and led the company to record results. The Supervisory Board of adidas AG is convinced that Bjorn Gulden will head adidas into a new era of strength and is looking very much forward to a successful cooperation," said Thomas Rabe, Chairman of the Supervisory Board of adidas AG. Reference Link

07:04 EST Amcor invests $3M in PulPac - Amcor has announced its investment of $3M in PulPac, a Swedish company providing disruptive manufacturing technology for low-cost, high-performance fiber-based packaging. Amcor is one of several strategic investors in a cross-industry alliance aimed at driving the deployment of PulPac's technology globally. PulPac is an innovation-led company focused on developing its dry-molded fiber technology for use as a viable, sustainable option for the packaging industry. This solution uses raw materials readily found globally, manufactured using an innovative process that requires significantly less resources, which reduces CO2 emissions by 80%, compared to existing processes. This cross-industry investment will support PulPac's global commercialization ambitions, enabling the company to deploy its solutions across markets and provide the potential for applications in Amcor's own product ranges. The alliance with PulPac and investment into its fiber technology also follow the launch of the AmFiber platform earlier this year, through which Amcor aims to redefine the capabilities of traditional paper packaging, and build upon Amcor's extensive experience in paper and carton packaging.

07:02 EST Foghorn Therapeutics sees cash runway into 2025 - As of September 30, 2022, the Company had $373.5 million in cash, cash equivalents and marketable securities.

06:48 EST Reata sees cash and equivalents sufficient through end of 2024 - The Company reaffirms that its existing cash and cash equivalents and marketable debt securities will be sufficient to enable it to fund operations through the end of 2024.

06:39 EST Sage sees cash and equivalents of $1.3B at end of FY22 - Sage anticipates cash, cash equivalents and marketable securities of approximately $1.3B at the end of 2022; does not anticipate receipt of any milestone payments from collaborations in 2022; anticipates R&D and SG&A spending to increase as it advances planned and ongoing studies for SAGE-718 and SAGE-324 and prepares for the potential launch of zuranolone; believes its cash and cash equivalents, anticipated funding from ongoing collaborations, and potential revenue, will support its operations into 2025.

06:29 EST Nintendo sold 6.68M switch consoles in 1H vs. 8.28M last year - The company said, "Unit sales for the Nintendo Switch family of systems declined by 19.2% year-on-year to 6.68 million units in the first half, affected by factors including the semiconductor shortage. For software, sales for titles such as Splatoon 3 and Nintendo Switch Sports that were released during this fiscal year have continued to grow steadily, and titles released in previous fiscal years as well as titles from other software publishers have also performed well. The total number of million-seller titles during this fiscalyear has reached 15 titles. As a result of these factors, software unit sales grew by 1.6% year-on-year to 95.41 million units."

06:18 EST Galecto presents 'positive' data from Phase 1b/2a GULLIVER-2 trial - Galecto announced it will discuss topline data and additional analyses from its recently completed Phase 1b/2a GULLIVER-2 trial, including the observed statistically significant signs of liver protection, in a conference call and virtual webinar, Tuesday, November 8th at 8:00 a.m. ET. The study was selected for a late-breaking oral presentation at the American Association for the Study of Liver Diseases' The Liver Meeting 2022. Topline data showed statistically significant reductions in the liver enzymes ALT, AST and GGT, with encouraging reductions for ALP, after 12 weeks of treatment. GB1211 also demonstrated improvement and consistent signs of activity across biochemical liver function markers and markers of target engagement, apoptosis, and fibrosis, including reductions in galectin-3 and CK-18. Bilirubin, albumin, international normalized ratio and other biochemical measurements remained stable. These findings are unique even when compared to data from previous studies in patients with less severe liver disease and treated over longer periods of time, and suggest that GB1211 provided liver cell protection and improved liver status, further supporting clinical development in severe liver disease.

06:11 EST First Advantage raises share repurchase authorization by $100M - First Advantage announced that its Board of Directors has expanded and extended the company's share repurchase program announced last quarter. The company's Board of Directors has approved a $100M increase to the originally authorized $50M program and extended the program through December 31, 2023. No shares will be purchased from Silver Lake or its affiliates.

05:26 EST KKR to invest $400M in Serentica Renewables - KKR and Serentica Renewables, a decarbonization platform that seeks to enable the energy transition by providing complex clean energy solutions for energy-intensive, hard-to-abate industries, announced the signing of definitive agreements under which KKR will invest $400M in the company. Serentica looks to deliver round-the-clock clean energy solutions for large-scale, energy-intensive industrial customers.

05:18 EST Best Inc. receives noncompliance letter from NYSE - Best Inc. announced that it received a letter from the New York Stock Exchange, notifying the company that it was not in compliance with applicable price criteria in the NYSE's continued listing standards because, as of October 17, the average closing price of the company's American Depositary Shares was less than $1.00 per ADS over a consecutive 30 trading-day period.

05:14 EST HP Enterprise, VMware announce next phase of partnership - At VMware Explore 2022 Europe, Hewlett Packard Enterprise (HPE) and VMware (VMW) announced the next phase of this partnership with HPE GreenLake for VMware, bringing together HPE GreenLake and VMware Cloud to deliver a fully integrated solution with a pay-as-you-go hybrid cloud consumption model. HPE GreenLake for VMware will provide customers with a fully integrated and modern hybrid cloud experience. VMware Cloud can be fully integrated across the HPE GreenLake portfolio including HPE GreenLake for Private Cloud Enterprise and customers will be able to deploy on-premises, in colocation facilities or at the edge, all managed by HPE GreenLake.

05:06 EST WWE announces search for Africa's next WWE Superstar - WWE, in conjunction with its Sub-Saharan Africa broadcast partner SuperSport, has announced a continent-wide talent search to find Africa's next WWE Superstar. The campaign was announced today in Lagos, Nigeria, the host city for a multi-day tryout in February 2023.